Table 3.
High (%) | Low (%) | Sig. | OR (CI95%) | Sig. | ||
---|---|---|---|---|---|---|
Age | Under 20 years | 45 (41.7) | 63 (58.3) | 0.186 | 0.36 (0.05–2.81) | 0.332 |
20–29 years | 34 (45.3) | 41 (54.7) | 0.897 | 0.11 (0.02–0.79) | 0.028 | |
Over 30 years | 11 (84.6) | 2 (15.4) | 0.007 * | . | . | |
Sex | Females | 76 (45.2) | 92 (54.8) | 0.640 | 1.45 (0.54–3.91) | 0.459 |
Males | 14 (50) | 14 (50) | . | . | ||
Living area | Rural | 12 (57.1) | 9 (42.9) | 0.357 * | 1.53 (0.57–4.10) | 0.400 |
Urban | 78 (44.6) | 97 (55.4) | . | . | ||
Specialty | Pharmacy | 10 (43.5) | 13 (56.5) | 0.803 | 1.11 (0.38–3.25) | 0.855 |
Veterinary Sciences | 13 (81.3) | 3 (18.8) | 0.004 * | 6.71 (1.23–36.77) | 0.028 | |
NLS | 12 (52.2) | 11 (47.8) | 0.522 | 3.45 (0.93–12.84) | 0.065 | |
Medicines (dental) | 52 (39.7) | 79 (60.3) | 0.013 | . | . | |
Educational level | 4–5 years | 21 (60) | 14 (40) | 0.065 | 1.52 (0.42–5.56) | 0.524 |
6–7 years | 15 (50) | 15 (50) | 0.626 | 2.04 (0.54–7.66) | 0.293 | |
1–3 years | 54 (41.2) | 77 (58.8) | 0.061 | . | . | |
Influenza vaccine | Yes | 21 (35) | 39 (65) | 0.042 | 0.42 (0.21–0.85) | 0.016 |
No | 69 (50.7) | 67 (49.3) | . | . | ||
COVID-19 vaccine | Yes | 23 (53.5) | 20 (46.5) | 0.260 | 1.78 (0.73–4.30) | 0.203 |
No | 67 (43.8) | 86 (56.2) | . | . |
NLS, Natural and Life Science. Bold character indicates significant results with a statistical difference (Sig. < 0.05) using Chi-squared or Fisher (indicated by an Asterisk (*)) tests.